Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.12
ENDP's Cash-to-Debt is ranked lower than
92% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. ENDP: 0.12 )
Ranked among companies with meaningful Cash-to-Debt only.
ENDP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.72 Max: No Debt
Current: 0.12
0.03
No Debt
Debt-to-Equity -1166.18
ENDP's Debt-to-Equity is ranked lower than
100% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ENDP: -1166.18 )
Ranked among companies with meaningful Debt-to-Equity only.
ENDP' s Debt-to-Equity Range Over the Past 10 Years
Min: -1166.18  Med: 1.34 Max: 17.07
Current: -1166.18
-1166.18
17.07
Debt-to-EBITDA -6.03
ENDP's Debt-to-EBITDA is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ENDP: -6.03 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ENDP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1820.95  Med: 0.6 Max: 5.32
Current: -6.03
-1820.95
5.32
Interest Coverage 0.76
ENDP's Interest Coverage is ranked lower than
96% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 132.39 vs. ENDP: 0.76 )
Ranked among companies with meaningful Interest Coverage only.
ENDP' s Interest Coverage Range Over the Past 10 Years
Min: 0.76  Med: 3.24 Max: 11.13
Current: 0.76
0.76
11.13
Piotroski F-Score: 5
Altman Z-Score: -1.05
Beneish M-Score: -3.41
WACC vs ROIC
3.78%
4.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 12.19
ENDP's Operating Margin % is ranked higher than
64% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. ENDP: 12.19 )
Ranked among companies with meaningful Operating Margin % only.
ENDP' s Operating Margin % Range Over the Past 10 Years
Min: 10.5  Med: 22.74 Max: 31.42
Current: 12.19
10.5
31.42
Net Margin % -75.58
ENDP's Net Margin % is ranked lower than
83% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. ENDP: -75.58 )
Ranked among companies with meaningful Net Margin % only.
ENDP' s Net Margin % Range Over the Past 10 Years
Min: -83.46  Med: -28.3 Max: 20.26
Current: -75.58
-83.46
20.26
ROE % -279.14
ENDP's ROE % is ranked lower than
94% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. ENDP: -279.14 )
Ranked among companies with meaningful ROE % only.
ENDP' s ROE % Range Over the Past 10 Years
Min: -279.14  Med: -42.19 Max: 20.43
Current: -279.14
-279.14
20.43
ROA % -19.74
ENDP's ROA % is ranked lower than
77% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. ENDP: -19.74 )
Ranked among companies with meaningful ROA % only.
ENDP' s ROA % Range Over the Past 10 Years
Min: -19.91  Med: -9.1 Max: 14.14
Current: -19.74
-19.91
14.14
ROC (Joel Greenblatt) % -387.39
ENDP's ROC (Joel Greenblatt) % is ranked lower than
83% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. ENDP: -387.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENDP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -515.52  Med: 44.62 Max: 728.96
Current: -387.39
-515.52
728.96
3-Year Revenue Growth Rate 0.80
ENDP's 3-Year Revenue Growth Rate is ranked lower than
67% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ENDP: 0.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENDP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12  Med: 18.9 Max: 26.9
Current: 0.8
-12
26.9
GuruFocus has detected 5 Warning Signs with Endo International PLC ENDP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENDP's 30-Y Financials

Financials (Next Earnings Date: 2018-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

ENDP Guru Trades in Q2 2017

Jim Simons 206,500 sh (New)
Diamond Hill Capital 488,244 sh (New)
Steven Cohen 3,156,400 sh (+77.78%)
Joel Greenblatt 1,023,962 sh (+37.55%)
Mario Gabelli 62,700 sh (+5.56%)
George Soros 250,000 sh (unchged)
Francis Chou 950,000 sh (unchged)
Larry Robbins 10,378,390 sh (unchged)
Pioneer Investments 28,618 sh (unchged)
Arnold Schneider 631,311 sh (-1.71%)
John Paulson 7,174,490 sh (-8.48%)
Paul Tudor Jones 54,796 sh (-52.11%)
Ray Dalio 1,539,408 sh (-59.76%)
» More
Q3 2017

ENDP Guru Trades in Q3 2017

Jim Simons 2,375,000 sh (+1050.12%)
Mario Gabelli 110,500 sh (+76.24%)
Diamond Hill Capital 716,670 sh (+46.79%)
Ray Dalio 1,972,219 sh (+28.12%)
Joel Greenblatt 1,203,214 sh (+17.51%)
Larry Robbins 10,953,261 sh (+5.54%)
George Soros 250,000 sh (unchged)
John Paulson 7,174,490 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Francis Chou 950,000 sh (unchged)
Pioneer Investments 28,618 sh (unchged)
Arnold Schneider Sold Out
Paul Tudor Jones 40,293 sh (-26.47%)
Steven Cohen 2,309,904 sh (-26.82%)
» More
Q4 2017

ENDP Guru Trades in Q4 2017

Paul Tudor Jones 168,987 sh (+319.40%)
Pioneer Investments 96,033 sh (+235.57%)
Jim Simons 6,736,360 sh (+183.64%)
Larry Robbins 19,238,422 sh (+75.64%)
Diamond Hill Capital 992,669 sh (+38.51%)
Ray Dalio 2,122,848 sh (+7.64%)
George Soros 2,000,000 sh (unchged)
John Paulson 7,174,490 sh (unchged)
Mario Gabelli 102,350 sh (-7.38%)
Steven Cohen 1,252,000 sh (-45.80%)
Joel Greenblatt 466,415 sh (-61.24%)
Francis Chou 80,000 sh (-91.58%)
» More
Q1 2018

ENDP Guru Trades in Q1 2018

Francis Chou 880,000 sh (+1000.00%)
John Paulson 9,174,500 sh (+27.88%)
Jim Simons 8,034,900 sh (+19.28%)
Larry Robbins 21,488,422 sh (+11.70%)
Diamond Hill Capital 1,089,659 sh (+9.77%)
Paul Tudor Jones 159,567 sh (-5.57%)
Mario Gabelli 93,100 sh (-9.04%)
Pioneer Investments 57,541 sh (-40.08%)
Ray Dalio 762,715 sh (-64.07%)
Steven Cohen 292,100 sh (-76.67%)
Joel Greenblatt 23,666 sh (-94.93%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2018-03-31 Add 27.88%0.26%$5.79 - $8.86 $ 11.2261%9,174,500
Mario Gabelli 2018-03-31 Reduce -9.04%$5.79 - $8.86 $ 11.2261%93,100
Joel Greenblatt 2018-03-31 Reduce -94.93%0.05%$5.79 - $8.86 $ 11.2261%23,666
Joel Greenblatt 2017-12-31 Reduce -61.24%0.09%$5.88 - $9.09 $ 11.2250%466,415
Mario Gabelli 2017-12-31 Reduce -7.38%$5.88 - $9.09 $ 11.2250%102,350
Joel Greenblatt 2017-09-30 Add 17.51%0.02%$7.55 - $12.38 $ 11.2216%1,203,214
Mario Gabelli 2017-09-30 Add 76.24%$7.55 - $12.38 $ 11.2216%110,500
Arnold Schneider 2017-09-30 Sold Out 1.34%$7.55 - $12.38 $ 11.2216%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:SZSE:002435, TSE:4547, TSX:APH, NAS:PCRX, SZSE:300485, SZSE:002550, ROCO:6446, SHSE:600557, BOM:524494, NAS:IPXL, SHSE:600993, NAS:RDUS, XBRU:FAGR, SZSE:300725, TSE:4569, SHSE:600750, SHSE:603676, XKRX:003520, BOM:533573, NYSE:MNK » details
Traded in other countries:ENDP.Canada, EO7.Germany,
Headquarter Location:Ireland
Endo International PLC is a generics and specialty branded pharmaceutical company. The company sells generic products in the US which includes pain management, urology, central nervous system disorders, immunosuppression, and oncology and among others.

After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The recent acquisitions of Auxilium and Par have increased the company's presence in urology and generics, respectively. Branded drugs represent approximately 30% of revenue with the remainder in generics.

Guru Investment Theses on Endo International PLC

Weitz Value Fund Comments on Endo International - Apr 27, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) left less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter of 2016 and refocus our capital in more attractive opportunities.



From Weitz Value Fund first quarter 2017 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jan 26, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Endo - Nov 08, 2016

Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.

From Wallace Weitz (Trades, Portfolio)'s Partners Value Fund third-quarter commentary.

Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jul 20, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Top Ranked Articles about Endo International PLC

Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States
Francis Chou’s Valeant Hits Almost 2-Year High Stock is rebounding from 2015 disaster
Bargain-hunting investor Francis Chou (Trades, Portfolio) scooped up Valeant shares in 2016 after several events decimated its stock price and other prominent investors, including Bill Ackman (Trades, Portfolio) and the Sequoia Fund, fled. But the company has been rallying since June to prices not hit since September 2017. Read more...
Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order
HollyFrontier, Broadridge Financial Solutions Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Consolidated Research: 2018 Summary Expectations for Summit Therapeutics, Orbotech, Amphastar Pharmaceuticals, Mizuho Financial Group, Endo International plc, and AXT — Fundamental Analysis, Key Performance Indications
Francis Chou Plunges Into Valeant and Endo in 1st Quarter Valeant CEO gives strong restructuring initiatives
Francis Chou (Trades, Portfolio), portfolio manager of Chou America Mutual Funds, disclosed he expanded his positions in Valeant Pharmaceuticals International Inc. (VRX) and Endo International PLC (NASDAQ:ENDP) during the first quarter. Read more...
Endo to Participate at the UBS Global Healthcare Conference
Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot Topics Symposium At The Aesthetic Meeting 2018
Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited
Endo Receives Paragraph IV Notification on Vasostrict®

Ratios

vs
industry
vs
history
Forward PE Ratio 4.92
ENDP's Forward PE Ratio is ranked higher than
97% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. ENDP: 4.92 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PS Ratio 0.78
ENDP's PS Ratio is ranked higher than
94% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. ENDP: 0.78 )
Ranked among companies with meaningful PS Ratio only.
ENDP' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.83 Max: 6.03
Current: 0.78
0.33
6.03
Price-to-Free-Cash-Flow 8.03
ENDP's Price-to-Free-Cash-Flow is ranked higher than
94% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.03 vs. ENDP: 8.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENDP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.25  Med: 8.4 Max: 2020.95
Current: 8.03
3.25
2020.95
Price-to-Operating-Cash-Flow 5.76
ENDP's Price-to-Operating-Cash-Flow is ranked higher than
95% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.21 vs. ENDP: 5.76 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENDP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.51  Med: 7.81 Max: 156.75
Current: 5.76
2.51
156.75
EV-to-EBIT -4.34
ENDP's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. ENDP: -4.34 )
Ranked among companies with meaningful EV-to-EBIT only.
ENDP' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: 6.1 Max: 49.7
Current: -4.34
-47.1
49.7
EV-to-EBITDA -7.12
ENDP's EV-to-EBITDA is ranked lower than
99.99% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. ENDP: -7.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENDP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -178.2  Med: 5.9 Max: 24.8
Current: -7.12
-178.2
24.8
EV-to-Revenue 3.11
ENDP's EV-to-Revenue is ranked higher than
59% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ENDP: 3.11 )
Ranked among companies with meaningful EV-to-Revenue only.
ENDP' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.7 Max: 8.8
Current: 3.11
1.2
8.8
Current Ratio 1.06
ENDP's Current Ratio is ranked lower than
90% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ENDP: 1.06 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.79 Max: 3.55
Current: 1.06
0.84
3.55
Quick Ratio 0.88
ENDP's Quick Ratio is ranked lower than
83% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. ENDP: 0.88 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.53 Max: 3.34
Current: 0.88
0.61
3.34
Days Inventory 83.68
ENDP's Days Inventory is ranked higher than
71% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. ENDP: 83.68 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 77.56  Med: 96.47 Max: 148.08
Current: 83.68
77.56
148.08
Days Sales Outstanding 53.61
ENDP's Days Sales Outstanding is ranked higher than
70% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. ENDP: 53.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.61  Med: 98.15 Max: 171.52
Current: 53.61
53.61
171.52
Days Payable 16.22
ENDP's Days Payable is ranked lower than
94% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. ENDP: 16.22 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 13.98  Med: 104.31 Max: 219.17
Current: 16.22
13.98
219.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.20
ENDP's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. ENDP: -13.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENDP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -8.9 Max: 4.7
Current: -13.2
-26.1
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.82
ENDP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. ENDP: 0.82 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENDP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.39  Med: 0.68 Max: 2.28
Current: 0.82
0.39
2.28
Price-to-Median-PS-Value 0.44
ENDP's Price-to-Median-PS-Value is ranked higher than
98% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. ENDP: 0.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENDP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.57 Max: 4.52
Current: 0.44
0.23
4.52
Price-to-Peter-Lynch-Fair-Value 5.08
ENDP's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 188 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. ENDP: 5.08 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ENDP' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.83 Max: 54.35
Current: 5.08
0
54.35
Earnings Yield (Greenblatt) % -23.09
ENDP's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. ENDP: -23.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENDP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -48.1  Med: 3.4 Max: 25.9
Current: -23.09
-48.1
25.9
Forward Rate of Return (Yacktman) % 44.79
ENDP's Forward Rate of Return (Yacktman) % is ranked higher than
99% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.53 vs. ENDP: 44.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ENDP' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.3  Med: 27.65 Max: 44.79
Current: 44.79
4.3
44.79

More Statistics

Revenue (TTM) (Mil) $3,131.79
EPS (TTM) $ -10.60
Beta-0.17
Volatility67.32%
52-Week Range $5.27 - 12.52
Shares Outstanding (Mil)223.79

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 2,731 2,763 2,818
EBIT (Mil $) 894 954 1,085
EBITDA (Mil $) 1,213 1,226 1,196
EPS ($) -1.52 0.06 0.45
EPS without NRI ($) -1.52 0.06 0.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-10.38%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}